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Introduction
A large number of cancer patients reportedly receive intra-
venous ascorbic acid (IV AA) with or without concomitant 
chemotherapy, often in nonconventional health care set-
tings.1 Although IV AA generally is regarded as safe, there 
are limitations to the currently available data. Clinically, 
ascorbic acid has been administered intravenously in doses 
as high as 200 g/d without adverse consequences.2 We have 
previously published initial safety data for doses of 75 and 
100 g IV AA in patients with metastatic pancreatic cancer 
receiving the combination of gemcitabine, erlotinib, and IV 
AA.3 We did not find significant adverse events beyond 
what was expected from the chemotherapy alone.
A phase I study at McGill University4 of 24 patients 
with terminal cancers reported no toxicity at IV AA doses 
of up to 125g. Another study involved 9 patients with 
metastatic pancreatic cancer who received gemcitabine, 
and IV AA showed no dose-limiting toxicity at similar 
doses.5 A more recent phase I-II study by Hoffer et al6 
evaluated adverse events in 14 patients with advanced 
cancers receiving high-dose IV AA in combination with 
cytotoxic chemotherapy. The authors reported that the IV 
AA was overall safe and well tolerated, though some 
patients had transient adverse events such as nausea or 
vomiting during or shortly after IV AA infusions.
Because ascorbic acid is broken down to oxalic acid, 
there has been concern that high-dose IV AA could 
potentially cause oxalate kidney stones, especially in patients 
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Abstract
Background. Intravenous ascorbic acid (IV AA) has been used extensively in cancer patients throughout the United States. 
Currently, there are limited data on the safety and clinical effects of IV AA. The purpose of this study was to expand the 
current literature using a retrospective analysis of adverse events and symptomatic changes of IV AA in a large sample 
of cancer patients. Methods. We conducted a retrospective chart review of all patients receiving IV AA for cancer at the 
Thomas Jefferson University Hospital over a 7-year period. We assessed all reports of adverse events, laboratory findings, 
and hospital or emergency department admissions. We also reviewed quality-of-life data, including fatigue, nausea, pain, 
appetite, and mood. Results. There were 86 patients who received a total of 3034 doses of IV AA ranging from 50 to 
150g. In all, 32 patients received only ascorbic acid as part of their cancer management (1197 doses), whereas 54 patients 
received ascorbic acid in conjunction with chemotherapy (1837 doses). The most common adverse events related to 
ascorbic acid were temporary nausea and discomfort at the injection site. All events reported in the ascorbic acid alone 
group were associated with less than 3% of the total number of infusions. Patients, overall, reported improvements in 
fatigue, pain, and mood while receiving ascorbic acid. Conclusions. The results of this retrospective analysis support the 
growing evidence that IV AA is generally safe and well tolerated in patients with cancer, and may be useful in symptom 
management and improving quality of life.
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with preexisting renal dysfunction. Renal dysfunction would 
lead to longer dwell time of ascorbate in the high pH envi-
ronment of the renal extracellular fluid and urinary space 
with consequent calcium oxalate precipitation. A large epi-
demiological study of 48 850 men by Thomas et al7 showed 
that individuals taking oral ascorbic acid were at an increased 
risk for developing kidney stones and that the incidence 
increased in men taking the highest doses. The most recent 
large epidemiological study based on the Health Professionals 
Follow-up Study has similarly shown that higher daily vita-
min C intake is associated with an increased risk of develop-
ing kidney stones in men, but not in women.8 There have 
been several case reports of renal failure associated with 
oxalate crystal formation in patients with preexisting kidney 
disorders who received high doses of oral vitamin C9 and IV 
vitamin C.10,11 It is not determined if these data indicate an 
increased risk of developing kidney stones in patients with 
normal renal function receiving intermittent high IV doses. 
However, it is essential to measure creatinine in patients 
prior to receiving IV AA and to intermittently monitor kid-
ney function throughout the time period while receiving 
infusions to ensure that kidney function is not affected.
A few reports and reviews suggest that IV AA might 
improve clinical symptoms such as fatigue or nausea asso-
ciated with either the cancer itself or resulting from the 
effects of chemotherapy medications.12-14 A phase I study 
showed improvements in global, physical, emotional, and 
social well-being as well as reduction in fatigue, nausea, 
pain, dyspnea, and insomnia.15 However, these measures 
were not evaluated for statistical significance.
Overall, the available data suggest that serious adverse 
events related to high-dose IV AA are uncommon, though 
caution is warranted in patient subgroups, such as those 
with renal disease. The phase I and safety studies to date 
have either focused on a particular patient group and/or 
have very small numbers. This article provides the first 
analysis of safety data for IV AA in a large, heterogeneous 
population of cancer patients in a setting that may be more 
representative of common clinical practice. We also provide 
a secondary analysis of impact on clinical symptoms. Our 
goal in presenting these data is to provide additional infor-
mation on safety of current practices and to inform next 
steps of clinical investigation.
Methods
This retrospective study was approved by the Thomas 
Jefferson University Institutional Review Board (IRB No. 
13D.154, originally approved on April 1, 2013) as a retro-
spective evaluation of existing clinical data and was con-
ducted according to the principles expressed in the 
Declaration of Helsinki.
This was a retrospective study covering a 7-year period 
from 2007 to 2014 of all cancer patients presenting to the 
Marcus Institute of Integrative Health, Thomas Jefferson 
University, who received treatment with IV AA. Patients 
included had a diagnosis of cancer and had received at least 
5 doses of IV AA. We established a minimum of 5 doses to 
ensure sufficient use of the IV AA to evaluate directly 
related effects. The dosage range was 50 to 150 g. For all 
patients, the ascorbic acid was mixed in a 1-L bag of 5% 
dextrose in water with enough fluid removed in order to 
mix in the ascorbic acid along with magnesium chloride and 
calcium gluconate. The IV AA was infused over 2 to 3 hours 
as tolerated by the patient. The dose was determined by the 
clinical judgment of the treating physician.
All patients had a normal glucose-6-phosphate dehy-
drogenase (G6PD) level prior to initiating the IV AA. It is 
the Marcus Institute clinical policy to check the G6PD 
enzyme level because of its role in the production of 
reduced nicotinamide adenine dinucleotide phosphate in 
the hexose-monophosphate shunt16 and subsequently in 
the generation of reduced glutathione in the red cell for 
protection against oxidative stress. Because high doses of 
IV AA result in the production of hydrogen peroxide, 
those individuals without the G6PD enzyme will experi-
ence significant hemolysis of the red blood cells.17 All 
patients had kidney function checked prior to initiating IV 
AA. The clinic policy requires all patients to have a nor-
mal creatinine level and monitored creatinine levels at 
regular intervals depending on the frequency of infusions. 
The clinic guidelines also exclude patients with a history 
of recurrent kidney stones.
The standard IV AA infusion was performed using the 
following general procedures. When patients arrived, their 
blood pressure, heart rate, respiratory rate, and temperature 
were obtained at baseline. The IV was started either periph-
erally or through an indwelling port. Infusions were pre-
pared with the prescribed dose of IV AA mixed with 
approximately 1 g of magnesium chloride and 1 g of cal-
cium gluconate. The infusion was run in over 2 to 3 hours. 
The speed of the infusion was adjusted to tolerance by the 
patient because the large hyperosmolar load can result in 
symptoms such as thirst, polyuria, and abdominal or chest 
discomfort. When patients experienced symptoms such as 
these or nausea or lightheadedness, the infusion rate was 
slowed until the symptoms improved. If the symptoms 
improved, the infusion proceeded at a lower rate. If the 
symptoms did not improve, that particular infusion was 
stopped, and the patient was evaluated prior to restarting 
future infusions. Vital signs were monitored throughout the 
infusion period and then once more after the infusion was 
completed and the IV removed. The patients were assessed 
for any adverse effects and then discharged.
Data were obtained through a thorough chart review, 
including physician and nursing notes, laboratory values 
(complete metabolic profile, complete blood count, and 
liver function tests when available), imaging studies, 
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emergency room visits, and hospital admissions during the 
treatment period. Adverse events were evaluated by stan-
dard National Cancer Institute clinical criteria 4.0.18
Analyses
The number of adverse events in the patients receiving IV 
AA alone compared with those receiving ascorbic acid in 
combination with chemotherapy was compared using a 
Fisher exact test. We also performed a qualitative assess-
ment of clinical symptoms such as fatigue, mood, or appe-
tite, which were evaluated based on patient reports described 
in the clinical charts. Patients are routinely asked at each 
visit for any changes in their symptoms. For each symptom 
reported initially (ie, prior to starting IV AA), we evaluated 
whether patients reported improved, stable, or worsening of 
that symptom. We included only symptoms that were ini-
tially reported by patients; so if a person had no nausea to 
begin with and did not develop any, then that symptom is 
not included in the table. Any symptoms that arose during 
treatment were considered to represent worsening (ie, the 
new onset of edema). For mood, we utilized clinical report 
data routinely collected as part of the Marcus Institute clini-
cal procedures, including the subjective report of mood, 
depressed feelings, anxiety, major stressors, or other psy-
chosocial issues. Patients who develop symptoms are rou-
tinely asked whether their symptoms were improved, stable, 
or worse compared with the prior visit. Appetite/weight loss 
was reported and measured in all patients. If there was no 
change in reported appetite and if the weight was within 5% 
during the period that the patient was receiving IV AA, it 
was regarded as stable. Weight gain and appetite improve-
ment are reported as “improved,” whereas the new onset of 
weight loss or loss of appetite are reported as “worsening” 
(no patients were found who were purposely trying to lose 
weight during their treatment period). In addition, the num-
ber of patients reporting improved or stable symptoms in 
each symptom category was compared with the number of 
patients reporting worsening symptoms using the Fisher 
exact test.
Results
Overall, 86 cancer patients were treated between 2007 and 
2014, with a total of 3083 doses of IV AA given (median 
number of doses per patient was 27). There were 56 women 
and 30 men with a median age of 60 years (range 19-87). 
This was a heterogeneous patient group in terms of cancer 
diagnosis and staging. The cancer types for the entire cohort 
are shown in Table 1. A total of 54 patients received the IV 
AA in combination with chemotherapy (which included 
drugs such as paclitaxel, carboplatin, sorafenib, irinotecan, 
and gemcitabine). The other 32 patients only received the 
ascorbic acid. There were no significant differences in can-
cer types, although all the pancreatic cancer patients but one 
received chemotherapy.
Adverse events for the entire group, divided into those 
receiving ascorbic acid alone and also in combination with 
chemotherapy, are provided in Table 2. The table reveals 
adverse events common in those patients receiving chemo-
therapy such as reductions in platelets and hemoglobin. 
These adverse events are known to be associated with the 
chemotherapy regimens received. Only 2 patients receiving 
IV AA alone had mild reductions in hemoglobin levels, and 
both had a history of anemia prior to receiving the infu-
sions. Furthermore, their low hemoglobin levels improved 
without transfusions and while still receiving IV AA.
The most common adverse events were nausea and vom-
iting, headache, and discomfort at the injection site. Most of 
these symptoms were self-limited to the time of individual 
infusions. For all patients, adverse events were reported in 
less than 5% of all infusions. In patients receiving only the 
IV AA, adverse events were reported in less than 3% of all 
infusions.
Patients with underlying diabetes did not have additional 
adverse effects, but administration of the ascorbic acid is 
known to falsely elevate glucometer readings,19,20 and this 
was observed in 3 patients. One potentially problematic 
issue, observed in 5 patients (3 in conjunction with chemo-
therapy and 2 with IV AA alone), was worsening of baseline 
ascites or edema. With regard to laboratory assessments that 
were available on 71 patients, there were no significant 
changes in electrolytes, blood urea nitrogen, creatinine, or 
Table 1. Types of Cancer in Patients Receiving High-Dose IV 
AA.
Cancer Type
Patients With 
IV AA  
Alone (n)
Patients With  
IV AA Plus  
Chemotherapy (n)
Bladder 1 0
Breast 4 6
Colon 5 3
Endometrial 2 0
Ewing’s 0 1
Chronic lymphocytic 
leukemia
1 1
Hepatocellular 
carcinoma
4 1
Lung 2 5
Lymphoma 2 1
Mesothelioma 1 1
Ovarian 1 3
Pancreatic 1 29
Penile 1 0
Prostate 4 1
Total 32 54
Abbreviations: IV AA, intravenous ascorbic acid.
Bazzan et al 915
Table 2. Adverse Event Chart for Patients Divided Into Those Receiving Chemotherapy and Those Not Receiving Chemotherapy 
(Based on Standard NCI Criteria).
Adverse Event
IV AA + Chemotherapy, Number 
of Events (n = 54, 1837 doses)
IV AA Alone, Number of 
Events (n = 32, 1197 doses)
Pain at injection site
 Grade 1 7 8
Headache
 Grade 1 6 4
Cold/Chills
 Grade 1 4 1
Allergic reaction
 Grade 1 2 0
 Grade 3 0 2
Platelet count decreased
 Grade 1 9 0
 Grade 2 6 0
 Grade 3 2 0
Anemia
 Grade 2 12 1
 Grade 3 3 1
Neutrophil count decreased
 Grade 2 1 0
 Grade 3 5 0
Hyponatremia
 Grade 3 0 1
Hypokalemia
 Grade 4 1 0
Elevated glucose
 Grade 2 3 0
Blood pressure
 Hypotension (grade 3) 2 1
 Hypertension (grade 2, found on 
monitoring but without clinical 
symptoms)
5 4
Renal failure
 Grade 2 1 0
 Grade 3 0 1
Renal colic
 Grade 1 (kidney stone) 0 1
Ascites
 Grade 2 3 2
Gastrointestinal
 Nausea/Vomiting
  (Grade 1) 15 6
  (Grade 3) 2 0
 Biliary obstruction
  (Grade 2) 1 0
  (Grade 3) 3 0
 Obstruction/Ileus (grade 3) 1 0
 Gastric hemorrhage
  (Grade 2) 1 0
 Colonic hemorrhage
  (Grade 3) 1 0
  Ascites (grade 2) 1 0
(continued)
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Adverse Event
IV AA + Chemotherapy, Number 
of Events (n = 54, 1837 doses)
IV AA Alone, Number of 
Events (n = 32, 1197 doses)
Infection
 Conjunctival (grade 2) 1 0
 Urinary tract infection (grade 3) 2 1
 Pneumonia (grade 3) 2 1
Thromboembolic event
 Grade 3 2 0
 Grade 4 3 0
Myocardial infarction
 Grade 4 2 0
Total 109 35
Abbreviations: IV AA, intravenous ascorbic acid; NCI, National Cancer Institute.
Table 2. (continued)
liver function tests when the entire cohort of patients was 
evaluated as a whole or divided into ascorbic acid alone or in 
combination with chemotherapy. Decreases in total blood 
cell counts were observed in patients receiving chemother-
apy but generally not in those receiving ascorbic acid alone. 
No serious adverse events were observed in blood cell counts.
One potential concern with IV AA is the formation of 
oxalate crystals in the urine, which could lead to kidney 
stones or even oxalate nephropathy.10,11 In our cohort, there 
was 1 patient who developed an elevated creatinine while 
receiving ascorbic acid, but the workup, including urinaly-
sis and imaging, suggested that the worsening kidney func-
tion was related to recurrent infections and progressive 
lymphoma resulting in obstruction. No crystals were 
detected in the urine, and ascorbic acid was continued dur-
ing this time as determined by the medical oncology team, 
urologist, and patient because there were no other alterna-
tive treatments available. Another patient presented to the 
hospital with nausea and vomiting and was found to have an 
elevated creatinine, which normalized in 2 days after medi-
cal management that included IV hydration. A third patient 
was reported to have developed a kidney stone while on IV 
AA, but this was not associated with any renal problems.
The results with regard to symptomatic response are pro-
vided in Table 3. For all patients receiving IV AA, there was 
a significant improvement or stability in fatigue, bowel hab-
its, and pain symptoms (P < .05). A small number of patients 
with mood disturbances, such as depression, also generally 
reported improvements in their overall mood. Appetite and 
weight loss was improved in 15 patients and was not sub-
stantially altered in 70 patients. There were only 2 reports in 
which appetite was worsened or weight loss accelerated in 
the entire group.
Discussion
IV AA as cancer therapy was largely discarded several 
decades ago when 2 randomized trials of oral vitamin C 
therapy failed to demonstrate therapeutic benefit.21,22 
However, more recent pharmacokinetic modeling indicates 
that IV administration of ascorbic acid produces a 25-fold 
or greater plasma concentration than the same dose given 
orally.23 Chen et al24 have reported that ascorbic acid levels 
achievable in vivo only by IV infusion are selectively cyto-
toxic in vitro to various cancer cell lines but not to normal 
cells by a mechanism involving formation of hydrogen per-
oxide. This action of IV AA is consistent with a growing 
literature that reactive oxygen species play an important 
role in the mechanism of action of proven cancer treatments 
and that impaired oxygen-reduction balance in cancer cells 
might cause induced reactive oxygen species to selectively 
kill cancer cells.25,26 We recently confirmed this previous 
work with a series of cell line experiments and also observed 
that ascorbate deregulates cellular calcium homeostasis, 
thereby promoting cell death.27 There are also other pro-
posed mechanisms of action. Ascorbate functions as a 
cofactor for a group of enzymes (Fe and 2-oxoglutarate-
dependent dioxygenases) such as hypoxia inducible factor 
(HIF) hydroxylases, which affect HIF protein levels through 
marking HIF for proteosomal degradation and also cotrans-
cription factor binding. High levels of ascorbate result in 
lower expression of HIF, which decreases tumor growth 
and increases sensitivity of cancer cells to the toxic effects 
of vitamin C.28 Ascorbate also increases the ten-eleven trans-
location enzyme activity associated with DNA demethyl-
ation, hence regulating gene transcription associated with 
cancer formation.29 Thus, it is possible that this mechanism 
represents an additional role for ascorbate in modulating 
genome activity that could affect tumor cells and growth.
Several small studies, including a phase I study by our 
group, have reported on the initial safety and effectiveness 
of IV AA, given either alone or with other agents.3,4,6 Overall, 
these studies have suggested that high-dose IV AA is rela-
tively safe and well tolerated, with or without concomitant 
chemotherapy. In this article we reported on a clinical expe-
rience of administering IV AA that may be reflective of a 
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Table 3. Number of Patients Reporting Improvement, Stability, or Worsening of Specific Symptoms (n = 86 Total Cancer Patients).
Change in 
Symptoms Fatigue
Diarrhea/
Constipation Pain
Appetite/
Weight Loss
Ascites/
Edema Mood
Worse 5 2 4 2 4 0
Stable 15 5 9 69 1 1
Improved 20 6 11 15 0 6
n = 54 Cancer patients receiving chemotherapy (1837 doses)
Worse 4 2 3 1 3 0
Stable 10 3 7 44 1 1
Improved 10 6 10 9 0 4
n = 32 Cancer patients without chemotherapy (1197 doses)
Worse 1 0 1 1 1 0
Stable 5 2 2 25 0 0
Improved 10 0 1 6 0 2
more typical environment and patient population for this 
treatment versus a more controlled research environment. 
For this reason, we retrospectively evaluated all patients 
with cancer treated with IV AA at the Marcus Institute over 
a 7-year period. The results of the present analysis are based 
on 86 patients who received IV AA in doses between 50 and 
150 g. The total number of doses received was 3034.
In regard to adverse events, IV AA was generally well 
tolerated, with only 3% to 5% of all infusions associated 
with an adverse event. The most common adverse event 
was nausea and vomiting which was self-limited during 
infusions and resolved quickly afterward. Although the 
mechanism of these symptoms is not known, the anecdotal 
clinical experience has been that eating lightly helps miti-
gate them. Another common adverse effect was pain or dis-
comfort at the injection site. Common clinical practices to 
mitigate this issue is slowing the infusion rate. In patients 
expected to receive a substantial number of IV AA doses, 
consideration of a port-a-cath or permanent line is war-
ranted. Patients in the group receiving chemotherapy plus 
IV AA were found to have reductions in their blood counts 
consistent with the effect of chemotherapy. There was no 
evidence that IV AA alone had an impact on measured 
blood counts.
The 2 most potentially problematic adverse events relate 
to fluid collection and renal function. We had 5 patients 
with existing ascites or edema who experienced worsening 
of this symptom. Whereas the worsening may have simply 
been related to the progression of their disease, third spac-
ing is a clinical condition that should be watched carefully 
in patients receiving IV AA, which is a hypertonic solution 
typically given in a large quantity of fluid (ie, 750-1000 
mL). On the other hand, a report by Hoffer et al4 described 
a case in which IV AA substantially reduced a patient’s 
ascites by acting as an osmotic diuretic, and Ma et al30 also 
indicated a reduction in ascites with vitamin C in combina-
tion with chemotherapy in ovarian cancer. Given that our 
patients had worsening ascites and edema, future studies 
will have to better assess the impact of IV AA on patients 
with substantial third spacing of fluids.
Particular care should be taken when patients have 
preexisting impairment in renal function, which would 
make them unable to clear a hypertonic fluid load. 
Although this was not the case in our cohort, care should 
be taken when treating patients with known third spac-
ing, particularly if it is associated with lymphadenopathy 
that impairs venous return from the legs or is associated 
with a pericardial effusion. Additionally, given the poten-
tial for an osmotic diuresis, we noted that 2 patients had 
electrolyte abnormalities: one with hyponatremia and 
one with hypokalemia. Given the potential effect of IV 
AA on electrolytes, it is important to evaluate electro-
lytes at regular intervals, particularly in those patients 
with a history of impaired renal function, patients on 
diuretics or other medications that might affect electro-
lytes, and patients with a known history of electrolyte 
disturbances.
It is known that ascorbic acid increases urine oxalate, 
which suggests a potential risk for developing kidney 
stones.31 Furthermore, several studies have demonstrated 
an increased risk of kidney stone formation with oral sup-
plementation, particularly in men. However, other studies 
have suggested that high doses of AA may even be protec-
tive.32 Pharmacokinetic studies have also explored 
whether high doses of vitamin C might increase the risk 
of forming kidney stones. For example, one study of 16 
patients with advanced cancer found that when studied 
using correct procedures for handling, storing, and ana-
lyzing the urine, less than 0.5% of a large IV dose of 
ascorbic acid in people with normal renal function was 
found as oxalic acid.33
In the medical literature, several cases of acute oxalate 
nephropathy were reported in patients with preexisting 
renal insufficiency given large IV doses of vitamin C.9,10,11 
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In our evaluation, we found 2 patients with increased creati-
nine, and both cases were explained by causes other than 
ascorbic acid effects. We also had 1 patient who reported 
developing a kidney stone while receiving IV AA. The type 
of stone could not be ascertained, and thus, it is possible that 
the IV AA contributed to the formation of the kidney stone 
in this patient. However, it should be noted that the overall 
prevalence of kidney stones in the general population is 1% 
to 2%.34 Nonetheless, patients should be monitored regu-
larly for the possibility of developing renal impairment or 
kidney stones during the course of receiving IV AA.
It is noted that care must be taken in patients with diabe-
tes because AA can falsely elevate glucometer readings sub-
stantially (ie, values can range greater than 400 mg/dL).35 
Pharmacokinetic studies have generally observed an elimi-
nation half-life of approximately 2 hours,15,36 with the impli-
cation that glucometer readings could remain abnormal for 6 
to 8 hours postinfusion. Thus, it is important to remind 
patients with diabetes to be cautious with regard to treating 
themselves with added insulin if readings remain elevated 
after receiving IV AA. Patients should typically wait until 
the following morning (ie, at least 6-8 hours) to recheck their 
glucose levels when the AA has been substantially elimi-
nated, so as not to interfere with glucose measurement.
The adverse events analysis of this retrospective study 
will hopefully add more safety data regarding the use of IV 
AA in patients with cancer. The comparison of patients 
receiving IV AA with and without concomitant chemother-
apy also helps demonstrate which adverse events are more 
specifically attributable to the ascorbic acid rather than the 
chemotherapy. As expected, there were fewer toxicities in 
the group that received IV AA alone. It is not known if the 
group receiving both had fewer toxicities from the addition 
of IV AA, though a study by Ma et al30 of 25 ovarian cancer 
patients showed that those treated with IV AA along with 
carboplatin and paclitaxel had fewer grade 1 and 2 adverse 
events compared with those treated with the chemotherapy 
agents alone.
In terms of symptoms, this heterogeneous patient cohort, 
receiving IV AA alone or in combination with chemother-
apy, qualitatively described improvements in energy, nau-
sea, pain, and mood. These are common symptoms in 
cancer patients and have been a target for studies on the 
potential beneficial effect of ascorbic acid. For example, 
one prospective study of 60 patients with advanced cancer 
found that IV AA (25-100 g/session) administered twice a 
week resulted in statistically significant decreases in fatigue, 
insomnia, and constipation after 2 weeks, based on the 
European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30), 
and a reduction in pain after 4 weeks.37 It also should be 
noted that fatigue worsened in 5 patients after stopping 
ascorbic acid (3 were in the chemotherapy group and 2 were 
in the nonchemotherapy group). A systematic review of 
quality-of-life studies using vitamin C also showed some 
evidence for beneficial effect.13 These studies and the find-
ings from the present retrospective analysis all have limita-
tions that make it impossible to draw conclusions regarding 
effects on clinical symptoms. In addition, the Mg included 
in our infusions has also been suggested to improve mood 
in patients, although a recent randomized crossover trial of 
4 g Mg (whereas our infusions typically have 1 g Mg) did 
not find any benefit in patients with treatment-resistant 
depression.38 Future prospective studies that are random-
ized and controlled with strong statistical analyses will be 
necessary to better assess any potential benefits of IV AA in 
cancer patients.
Limitations for this retrospective analysis include inher-
ent problems reviewing past clinical charts, which restricts 
the analysis to data that are available in those charts. Doses 
were determined based on the clinical decision of the treat-
ing physician, but future approaches to determining ways of 
standardizing the doses will be important for both research 
and clinical applications. As mentioned, complete labora-
tory data were not available on 16 patients, but there was no 
clinical evidence that these patients experienced untoward 
medical events that might have been related to laboratory 
abnormalities. Symptomatic reporting is also limited to 
what was reported by the patient and the physician. Because 
the patients were seen clinically, it was important to assess 
for adverse events, so it is unlikely that there is an underre-
porting of negative effects of the IV AA. However, it is cer-
tainly possible that symptomatic changes, for better or 
worse, were not included in the charts, thus preventing any 
firm conclusions. Furthermore, we might expect reporting 
bias in patients receiving the IV AA, and therefore, future 
studies should utilize more formal questionnaires and scales 
for the evaluation of subjective symptoms such as fatigue, 
mood, and pain. In addition, because this was a retrospec-
tive evaluation, there was no control group (ie, a placebo IV 
with just saline), which might have yielded similar symp-
tomatic changes. However, the ability to compare patients 
receiving IV AA with and without chemotherapy provides 
some knowledge as to which adverse events are more spe-
cific to the IV AA.
The results, and limitations, that arise from this retro-
spective analysis suggest the need for larger-scale random-
ized controlled trials to determine the ability of IV AA to 
improve the quality of life in cancer patients, especially 
those receiving chemotherapy.
Conclusion
In this systematic retrospective evaluation of 86 patients 
with cancer who were given a total of 3034 doses of IV AA, 
the treatment was found to be generally well tolerated and 
safe, with few adverse events reported. Also observed were 
subjective improvements in symptoms such as fatigue, 
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pain, and mood. Future studies should more specifically 
evaluate the mitigating effect of IV AA on adverse events 
related to chemotherapy and improvements in valid quality-
of-life measures as well as the potential effectiveness in the 
management of different types of cancer.
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